Francesco Angelico

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/6879931/publications.pdf

Version: 2024-02-01

84 papers

3,483 citations

32 h-index 56 g-index

85 all docs 85 docs citations

85 times ranked 5407 citing authors

#	Article	IF	CITATIONS
1	Strong association between non alcoholic fatty liver disease (NAFLD) and low 25(OH) vitamin D levels in an adult population with normal serum liver enzymes. BMC Medicine, 2011, 9, 85.	2.3	257
2	Increased Liver Localization of Lipopolysaccharides in Human and Experimental NAFLD. Hepatology, 2020, 72, 470-485.	3.6	203
3	Liver vitamin D receptor, CYP2R1, and CYP27A1 expression: relationship with liver histology and vitamin D3 levels in patients with nonalcoholic steatohepatitis or hepatitis C virus. Hepatology, 2012, 56, 2180-2187.	3.6	192
4	Oxidative stress: New insights on the association of non-alcoholic fatty liver disease and atherosclerosis. World Journal of Hepatology, 2015, 7, 1325.	0.8	152
5	Non-alcoholic fatty liver syndrome: A hepatic consequence of common metabolic diseases. Journal of Gastroenterology and Hepatology (Australia), 2003, 18, 588-594.	1.4	149
6	Nonalcoholic Fatty Liver Disease and Fibrosis AssociatedÂWith Increased Risk of Cardiovascular EventsÂinÂaÂProspective Study. Clinical Gastroenterology and Hepatology, 2020, 18, 2324-2331.e4.	2.4	136
7	No effects of oral vitamin D supplementation on non-alcoholic fatty liver disease in patients with type 2 diabetes: a randomized, double-blind, placebo-controlled trial. BMC Medicine, 2016, 14, 92.	2.3	130
8	The efficacy and safety of statins for the treatment of non-alcoholic fatty liver disease. Digestive and Liver Disease, 2015, 47, 4-11.	0.4	121
9	Adherence to Mediterranean Diet and Non-Alcoholic Fatty Liver Disease: Effect on Insulin Resistance. American Journal of Gastroenterology, 2017, 112, 1832-1839.	0.2	109
10	New Insights into the Pathogenesis of Non-Alcoholic Fatty Liver Disease: Gut-Derived Lipopolysaccharides and Oxidative Stress. Nutrients, 2020, 12, 2762.	1.7	89
11	Obesity and Hypercholesterolemia are Associated with NOX2 Generated Oxidative Stress and Arterial Dysfunction. Journal of Pediatrics, 2012, 161, 1004-1009.	0.9	74
12	Oxidative stress mediated arterial dysfunction in patients with obstructive sleep apnoea and the effect of continuous positive airway pressure treatment. BMC Pulmonary Medicine, 2012, 12, 36.	0.8	74
13	The role of nutraceuticals for the treatment of nonâ€elcoholic fatty liver disease. British Journal of Clinical Pharmacology, 2017, 83, 88-95.	1.1	74
14	NOX2-generated oxidative stress is associated with severity of ultrasound liver steatosis in patients with non-alcoholic fatty liver disease. BMC Gastroenterology, 2014, 14, 81.	0.8	71
15	Long-term prediction of adherence to continuous positive air pressure therapy for the treatment of moderate/severe obstructive sleep apnea syndrome. Sleep Medicine, 2018, 43, 66-70.	0.8	66
16	Drugs improving insulin resistance for non-alcoholic fatty liver disease and/or non-alcoholic steatohepatitis., 2007,, CD005166.		61
17	Modern approach to the clinical management of non-alcoholic fatty liver disease. World Journal of Gastroenterology, 2014, 20, 8341.	1.4	61
18	Oxidative stress-mediated arterial dysfunction in patients with metabolic syndrome: Effect of ascorbic acid. Free Radical Biology and Medicine, 2007, 43, 853-859.	1.3	60

#	Article	IF	CITATIONS
19	Incidence of Myocardial Infarction and Vascular Death in Elderly Patients With Atrial Fibrillation Taking Anticoagulants. Chest, 2015, 147, 1644-1650.	0.4	59
20	Evaluation of Polygenic Determinants of Non-Alcoholic Fatty Liver Disease (NAFLD) By a Candidate Genes Resequencing Strategy. Scientific Reports, 2018, 8, 3702.	1.6	59
21	Reduced Lysosomal Acid Lipase Activity in Adult Patients With Non-alcoholic Fatty Liver Disease. EBioMedicine, 2015, 2, 750-754.	2.7	51
22	Extra virgin olive oil improves post-prandial glycemic and lipid profile in patients with impaired fasting glucose. Clinical Nutrition, 2017, 36, 782-787.	2.3	50
23	Endothelial dysfunction and oxidative stress in children with sleep disordered breathing: Role of NADPH oxidase. Atherosclerosis, 2015, 240, 222-227.	0.4	49
24	Evaluation of the performance of Dutch Lipid Clinic Network score in an Italian FH population: The LIPIGEN study. Atherosclerosis, 2018, 277, 413-418.	0.4	48
25	Antioxidant supplements for non-alcoholic fatty liver disease and/or steatohepatitis. The Cochrane Library, 2007, , CD004996.	1.5	47
26	PNPLA3 variant and portal/periportal histological pattern in patients with biopsy-proven non-alcoholic fatty liver disease: a possible role for oxidative stress. Scientific Reports, 2017, 7, 15756.	1.6	45
27	Under-prescription of statins in patients with non-alcoholic fatty liver disease. Nutrition, Metabolism and Cardiovascular Diseases, 2017, 27, 161-167.	1.1	45
28	Obstructive sleep apnoea syndrome and the metabolic syndrome in an internal medicine setting. European Journal of Internal Medicine, 2010, 21, 191-195.	1.0	43
29	Weight loss is associated with improved endothelial dysfunction via NOX2-generated oxidative stress down-regulation in patients with the metabolic syndrome. Internal and Emergency Medicine, 2012, 7, 219-227.	1.0	42
30	Cardiovascular risk stratification in patients with non-valvular atrial fibrillation: the 2MACE score. Internal and Emergency Medicine, 2016, 11, 199-204.	1.0	41
31	Non-alcoholic fatty liver disease and subclinical atherosclerosis: A comparison of metabolically-versus genetically-driven excess fat hepatic storage. Atherosclerosis, 2017, 257, 232-239.	0.4	39
32	Role of silymarin as antioxidant in clinical management of chronic liver diseases: a narrative review. Annals of Medicine, 2022, 54, 1548-1560.	1.5	39
33	Remnant Lipoprotein Cholesterol and Cardiovascular and Cerebrovascular Events in Patients with Non-Alcoholic Fatty Liver Disease. Journal of Clinical Medicine, 2018, 7, 378.	1.0	36
34	Bleeding and thrombosis in cirrhotic patients: What really matters?. Digestive and Liver Disease, 2012, 44, 275-279.	0.4	34
35	Poor Adherence to Mediterranean Diet and Serum Lipopolysaccharide Are Associated with Oxidative Stress in Patients with Non-Alcoholic Fatty Liver Disease. Nutrients, 2020, 12, 1732.	1.7	33
36	Association between non-alcoholic fatty liver disease and obstructive sleep apnea. World Journal of Gastroenterology, 2020, 26, 2669-2681.	1.4	32

#	Article	IF	CITATIONS
37	Severity of OSAS, CPAP and cardiovascular events: A followâ€up study. European Journal of Clinical Investigation, 2018, 48, e12908.	1.7	31
38	Statin liver safety in nonâ€alcoholic fatty liver disease: A systematic review and metanalysis. British Journal of Clinical Pharmacology, 2022, 88, 441-451.	1.1	28
39	Non-alcoholic fatty liver disease and cardiovascular disease: epidemiological, clinical and pathophysiological evidences. Internal and Emergency Medicine, 2012, 7, 291-296.	1.0	27
40	Similar Reduction of Cholesterol-Adjusted Vitamin E Serum Levels in Simple Steatosis and Non-Alcoholic Steatohepatitis. Clinical and Translational Gastroenterology, 2015, 6, e113.	1.3	25
41	Gut-derived lipopolysaccharides increase post-prandial oxidative stress via Nox2 activation in patients with impaired fasting glucose tolerance: effect of extra-virgin olive oil. European Journal of Nutrition, 2019, 58, 843-851.	1.8	25
42	Relation of Nonalcoholic Fatty Liver Disease and Framingham Risk Score to Flow-Mediated Dilation in Patients With Cardiometabolic Risk Factors. American Journal of Cardiology, 2015, 115, 1402-1406.	0.7	24
43	Reduced lysosomal acid lipase activity: A new marker of liver disease severity across the clinical continuum of non-alcoholic fatty liver disease?. World Journal of Gastroenterology, 2019, 25, 4172-4180.	1.4	23
44	Added Fructose in Non-Alcoholic Fatty Liver Disease and in Metabolic Syndrome: A Narrative Review. Nutrients, 2022, 14, 1127.	1.7	22
45	HDL-Mediated Cholesterol Efflux and Plasma Loading Capacities Are Altered in Subjects with Metabolically- but Not Genetically Driven Non-Alcoholic Fatty Liver Disease (NAFLD). Biomedicines, 2020, 8, 625.	1.4	21
46	Statin use and mortality in atrial fibrillation: A systematic review and meta-analysis of 100,287 patients. Pharmacological Research, 2021, 165, 105418.	3.1	21
47	Does Nox2 Overactivate in Children with Nonalcoholic Fatty Liver Disease?. Antioxidants and Redox Signaling, 2019, 30, 1325-1330.	2.5	20
48	Mediterranean diet and physical activity impact on metabolic syndrome among children and adolescents from Southern Italy: Contribution from the Calabrian Sierras Community Study (CSCS). International Journal of Cardiology, 2016, 225, 284-288.	0.8	19
49	Severe reduction of blood lysosomal acid lipase activity in cryptogenic cirrhosis: A nationwide multicentre cohort study. Atherosclerosis, 2017, 262, 179-184.	0.4	19
50	Greater circulating DPP4 activity is associated with impaired flow-mediated dilatation in adults with type 2 diabetes mellitus. Nutrition, Metabolism and Cardiovascular Diseases, 2019, 29, 1087-1094.	1.1	19
51	Does Lysosomial Acid Lipase Reduction Play a Role in Adult Non-Alcoholic Fatty Liver Disease?. International Journal of Molecular Sciences, 2015, 16, 28014-28021.	1.8	18
52	A systematic review on the association between obstructive sleep apnea and chronic kidney disease. Sleep Medicine Reviews, 2020, 53, 101337.	3.8	18
53	Phenotypical heterogeneity linked to adipose tissue dysfunction in patients with TypeÂ2 diabetes. Clinical Science, 2016, 130, 1753-1762.	1.8	16
54	Spleen dimensions are inversely associated with lysosomal acid lipase activity in patients with non-alcoholic fatty liver disease. Internal and Emergency Medicine, 2017, 12, 1159-1165.	1.0	16

#	Article	IF	CITATIONS
55	Role of NADPH oxidase-2 and oxidative stress in children exposed to passive smoking. Thorax, 2018, 73, 986-988.	2.7	16
56	Lysosomal acid lipase activity and liver fibrosis in the clinical continuum of nonâ€alcoholic fatty liver disease. Liver International, 2019, 39, 2301-2308.	1.9	15
57	Recurrence of insulin resistant metabolic syndrome following liver transplantation. European Journal of Gastroenterology and Hepatology, 2003, 15, 99-102.	0.8	14
58	Oleuropein-enriched chocolate by extra virgin olive oil blunts hyperglycaemia in diabetic patients: Results from a one-time 2-hour post-prandial cross over study. Clinical Nutrition, 2020, 39, 2187-2191.	2.3	13
59	Gastric Cancer Precursor Lesions and Helicobacter pylori Infection in Patients with Partial Gastrectomy for Peptic Ulcer. World Journal of Surgery, 2005, 29, 1127-1130.	0.8	12
60	Moderate Weight Loss Decreases Oxidative Stress and Increases Antioxidant Status in Patients with Metabolic Syndrome. ISRN Obesity, 2012, 2012, 1-9.	2.2	12
61	Prevalence and Impact of Nonalcoholic Fatty Liver Disease in Atrial Fibrillation. Mayo Clinic Proceedings, 2020, 95, 513-520.	1.4	11
62	Effect of aspirin on renal disease progression in patients with type 2 diabetes: A multicenter, double-blind, placebo-controlled, randomized trial. The renaL disEase progression by aspirin in diabetic pAtients (LEDA) trial. Rationale and study design. American Heart Journal, 2017, 189, 120-127.	1.2	10
63	Reduced Lysosomal Acid Lipase Activity in Blood and Platelets Is Associated With Nonalcoholic Fatty Liver Disease. Clinical and Translational Gastroenterology, 2020, 11, e00116.	1.3	10
64	Open Issues in the Transition from NAFLD to MAFLD: The Experience of the Plinio Study. International Journal of Environmental Research and Public Health, 2021, 18, 8993.	1.2	10
65	Passive Smoking Exacerbates Nicotinamide-Adenine Dinucleotide Phosphate Oxidase Isoform 2–Induced Oxidative Stress and Arterial Dysfunction in Children with Persistent Allergic Rhinitis. Journal of Pediatrics, 2018, 202, 252-257.	0.9	9
66	AISF update on the diagnosis and management of adult-onset lysosomal storage diseases with hepatic involvement. Digestive and Liver Disease, 2020, 52, 359-367.	0.4	9
67	Chronic granulomatous disease as an SOS call for multicenter cooperative effort to prevent infections. Annals of Allergy, Asthma and Immunology, 2016, 117, 285-289.	0.5	7
68	Overexpression of the Vitronectin V10 Subunit in Patients with Nonalcoholic Steatohepatitis: Implications for Noninvasive Diagnosis of NASH. International Journal of Molecular Sciences, 2018, 19, 603.	1.8	7
69	Is the Mediterranean Diet the Best Approach to NAFLD Treatment Today?. Nutrients, 2021, 13, 739.	1.7	7
70	Assessment of hepatic fibrosis in MAFLD: A new player in the evaluation of residual cardiovascular risk?. Digestive and Liver Disease, 2021, 53, 383-384.	0.4	7
71	Attitudes and approach to cardiovascular risk factors in Italy: results of an electronic questionnaire survey. Public Health, 2003, 117, 242-249.	1.4	6
72	Impact of the New Metabolic-Associated Fatty Liver Disease (MAFLD) on NAFLD Patients Classification in Italy. Clinical Gastroenterology and Hepatology, 2021, 19, 2683-2684.	2.4	6

#	Article	IF	CITATIONS
73	Nonalcoholic Fatty Liver Disease and the Kidney: A Review. Biomedicines, 2021, 9, 1370.	1.4	6
74	Non-alcoholic fatty liver disease (NAFLD), metabolic syndrome and cardiovascular events in atrial fibrillation. A prospective multicenter cohort study. Internal and Emergency Medicine, 2021, 16, 2063-2068.	1.0	5
75	The challenge of cardiovascular prevention in NAFLD. The Lancet Gastroenterology and Hepatology, 2021, 6, 877-878.	3.7	5
76	Metabolic Syndrome but Not Fatty Liver-Associated Genetic Variants Correlates with Glomerular Renal Function Decline in Patients with Non-Alcoholic Fatty Liver Disease. Biomedicines, 2022, 10, 720.	1.4	5
77	High Compliance to Mediterranean Diet Associates with Lower Platelet Activation and Liver Collagen Deposition in Patients with Nonalcoholic Fatty Liver Disease. Nutrients, 2022, 14, 1209.	1.7	5
78	Oxidative stress mediated platelet activation in patients with congenital analbuminemia: Effect of albumin infusion. Journal of Thrombosis and Haemostasis, 2021, 19, 3090-3094.	1.9	4
79	Statins and nonâ€alcoholic fatty liver disease. Liver International, 2019, 39, 1787-1787.	1.9	3
80	Sex-Related Differences in the Association between Metabolic Syndrome and Gallstone Disease. International Journal of Environmental Research and Public Health, 2021, 18, 1958.	1.2	3
81	Strong interplay between metabolic syndrome, obstructive sleep apnoea, oxidative stress and arterial dysfunction. Sleep and Breathing, 2013, 18, 223-4.	0.9	2
82	Current Ways of Treating Dyslipidemias to Prevent Atherosclerosis. Therapeutic Apheresis and Dialysis, 2013, 17, 125-129.	0.4	1
83	Obstructive Sleep Apnea and the Metabolic Syndrome. , 2015, , 177-184.		0
84	Response to Duret et al American Journal of Gastroenterology, 2018, 113, 775-776.	0.2	0